NCT06788444 Efficacy of Esketamine for Patients With Irritable Bowel Syndrome
| NCT ID | NCT06788444 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Beijing Tiantan Hospital |
| Condition | Irritable Bowel Syndrome |
| Study Type | INTERVENTIONAL |
| Enrollment | 552 participants |
| Start Date | 2025-09-18 |
| Primary Completion | 2026-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 552 participants in total. It began in 2025-09-18 with a primary completion date of 2026-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
To explore the efficacy of a single low dose of esketamine for patients with irritable bowel syndrome (IBS).
Eligibility Criteria
Inclusion Criteria: 1. Age of 18 - 60 years; 2. American Society of Anesthesiologists (ASA) physical status of I - II; 3. Body Mass Index (BMI) of 15 - 30; 4. Scheduled for colonoscopy; 5. Positive screening results according to the Rome IV diagnostic criteria for IBS; 6. Patients who met Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) criteria for Anxiety disorder (ANXD) and/or major depressive disorder (MDD) . Exclusion Criteria: 1. GastrointestinalTract (GI) bleeding; 2. Any organic lesions confirmed by clinical examination, laboratory examination or colonoscopy； 3. A previous diagnosis of colon cancer, infammatory bowel disease or coeliac disease; 4. A history of weight loss (at least 10%) within six months; 5. A history of abdominal surgery (other than hernia repair or appendectomy); 6. Participate in other clinical trials within 3 months; 7. Patients older than 55 years of age who have not undergone a colonoscopy in the past 5 years； 8. Mental disorder patients with severe personality disorder, active suicidal ideation and history of self-harm within 1 year; 9. Allergy or any contraindications to the drugs used in the study, such as severe cardiovascular disease, refractory hypertension, or hyperthyroidism; 10. Drinking more than 50 units (1 unit refers to 10ml of pure alcohol) per week; 11. Pregnancy or breastfeeding.
Frequently Asked Questions
Who can join the NCT06788444 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 60 Years, studying Irritable Bowel Syndrome. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06788444 currently recruiting?
Yes, NCT06788444 is actively recruiting participants. Visit ClinicalTrials.gov or contact Beijing Tiantan Hospital to inquire about joining.
Where is the NCT06788444 trial being conducted?
This trial is being conducted at Beijing, China.
Who is sponsoring the NCT06788444 clinical trial?
NCT06788444 is sponsored by Beijing Tiantan Hospital. The trial plans to enroll 552 participants.